The Question That Doesn’t Seem to Go Away: Cancer Risk of Anti-TNF Therapy
- 17 February 2021
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Digestive Diseases and Sciences
- Vol. 67 (1), 6-7
- https://doi.org/10.1007/s10620-021-06883-w
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic ReviewJournal of Crohn's and Colitis, 2021
- Lymphoma in Pediatric-Onset Inflammatory Bowel Disease Treated with Infliximab Monotherapy: A Case SeriesDigestive Diseases and Sciences, 2021
- Cancer Risk in Pediatric-Onset Inflammatory Bowel Disease: A Population-Based Danish Cohort StudyGastroenterology, 2020
- Systematic review with meta‐analysis: comparative risk of lymphoma with anti‐tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2020
- Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964-2014BMJ, 2017
- Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Azathioprine and 6-Mercaptopurine: A Meta-analysisClinical Gastroenterology and Hepatology, 2015
- Risks of Serious Infection or Lymphoma With Anti–Tumor Necrosis Factor Therapy for Pediatric Inflammatory Bowel Disease: A Systematic ReviewClinical Gastroenterology and Hepatology, 2014
- Association Between Tumor Necrosis Factor-α Antagonists and Risk of Cancer in Patients With Inflammatory Bowel DiseaseJAMA, 2014
- Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's DiseaseGastroenterology, 2014
- Tumour necrosis factor and cancerNature Reviews Cancer, 2009